Outcome

The study indicates that hyperbaric oxygen therapy (HBOT) significantly improves cardiac function in asymptomatic patients with diabetes over 60 sessions. Key findings include an increase in ejection fraction from 60.71% to 62.29% a reduction in left ventricular end systolic volume from 38.08 ml to 35.39 ml and an enhancement in myocardial performance index from 0.29 to 0.26

Introduction

The utilization of Hyperbaric Oxygen Therapy (HBOT) has shown to improve heart function in asymptomatic patients with diabetes. This study evaluated the effects of a comprehensive 60-session course of HBOT on various echocardiographic parameters resulting in significant enhancements. Notably the ejection fraction increased from 60.71% to 62.29% indicating enhanced heart efficiency while the left ventricular end systolic volume decreased from 38.08 ml to 35.39 ml suggesting reduced cardiac workload. Additionally the myocardial performance index improved from 0.29 to 0.26 alongside marked improvements in left ventricular global longitudinal strain and twist indicating better left ventricular function particularly in the apical segments. These findings suggest that HBOT could be a promising intervention for enhancing cardiac performance and potentially serve as a beneficial treatment for patients with heart failure and systolic dysfunction.

Results

The study evaluated the impact of hyperbaric oxygen therapy (HBOT) on heart function in asymptomatic patients over 60 sessions. Significant improvements were observed in several echocardiographic parameters highlighting enhanced cardiac performance.

Notably there was an increase in ejection fraction which measures the percentage of blood the left ventricle pumps out with each contraction. This metric rose from 60.71 ± 6.02% to 62.29 ± 5.19% suggesting improved heart pumping efficiency. Concurrently left ventricular end systolic volume which indicates the volume of blood remaining in the left ventricle after contraction decreased from 38.08 ± 13.30 ml to 35.39 ± 13.32 ml reflecting a reduced cardiac workload.

The myocardial performance index a comprehensive measure of heart function also showed improvement decreasing from 0.29 ± 0.07 to 0.26 ± 0.08. Enhanced left ventricular function was further demonstrated through improvements in global longitudinal strain improving from -19.31 ± 3.17% to -20.16 ± 3.34% illustrating the heart muscle’s better contractile ability. The cardiac twist indicating the torsional motion of the heart during contraction increased significantly from 18.32 ± 6.61° to 23.12 ± 6.35° pointing to superior mechanical functionality.

These findings collectively suggest that HBOT significantly benefits left ventricular function and overall heart performance particularly in the apical segments. The data present a compelling case for potential broader use of HBOT as a treatment option for patients with heart failure and systolic dysfunction.

Conclusion

In conclusion this study underscores the potential efficacy of hyperbaric oxygen therapy (HBOT) in enhancing cardiac function in asymptomatic patients with diabetes. The 60-session HBOT regimen resulted in marked improvements in key echocardiographic parameters including an increase in ejection fraction a reduction in left ventricular end systolic volume and enhancements in myocardial performance index left ventricular global longitudinal strain and cardiac twist. These findings indicate that HBOT may reinforce left ventricular function particularly in the apical segments contributing to overall improved heart performance. The promising results suggest that HBOT holds significant potential as a therapeutic strategy for managing heart failure and systolic dysfunction. Future research should aim to validate these findings and explore the broader applicability of HBOT in diverse patient populations with cardiac conditions.